摘要：2025年美国临床肿瘤学会（ASCO）年会即将于5月30日至6月3日在美国芝加哥正式召开。作为全球肿瘤学领域规模最大、最具影响力的学术盛会之一，本届年会以“知识化为行动：共创美好未来（Driving Knowledge to Action: Building

2025年美国临床肿瘤学会（ASCO）年会即将于5月30日至6月3日在美国芝加哥正式召开。作为全球肿瘤学领域规模最大、最具影响力的学术盛会之一，本届年会以“知识化为行动：共创美好未来（Driving Knowledge to Action: Building a Better Future）”为主题，汇聚全球肿瘤领域权威专家，共同探讨癌症治疗的最新突破与临床实践创新。

2025年ASCO年会共收到7,775篇摘要，创历史新高，其中3,200篇摘要脱颖而出，将在口头摘要专场、临床科学研讨会、快速口头摘要专场及壁报专场中亮相。

于6月1日（周日）召开的全体大会（Plenary Session）将聚焦本年度五大重磅临床研究（LBA1、LBA2、LBA3、LBA4、LBA5），展开深度呈现与讨论，本文带您提前锁定重磅研究。

五大重磅研究

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).

讲者：Frank A. Sinicrope, MD | Mayo Clinic Rochester

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

讲者：Jean Bourhis Sr, MD, PhD | CHUV, Bâtiment Hospitalier

Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).

讲者：Andrew Tucker Kuykendall, MD | Moffitt Cancer Center

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.Camizestrant

讲者：Nicholas C. Turner, MD, PhD | Royal Marsden Hospital

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

讲者：Yelena Y. Janjigian, MD | Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center

来源 | 2025 ASCO年会官网

来源：壹生